SCHEMBL293102

SCHEMBL293102

[CH2]CC(=O)N1CCOCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
TSHR P16473 3/20 0.54
ALOX15 P16050 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 2/20 0.48
GAA P10253 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA9 Q16790 1/20 0.48
GLA P06280 1/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 1/20 0.46
FKBP1A P62942 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.45
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL295077 0.82 L3MBTL1 (0.55) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL3753324 0.80 L3MBTL1 (0.64) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL3404224 0.79 L3MBTL1 (0.63) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL294529 0.79 GLA (0.59) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL424000 0.78 L3MBTL1 (0.68) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL13522679 0.78 L3MBTL1 (0.61) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL423999 0.78 L3MBTL1 (0.61) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL2262931 0.78 L3MBTL1 (0.61) L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2
SCHEMBL206420 0.77
SCHEMBL6050166 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2017-11-02 US claimed
EP-2440517-B1 CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2014-03-26 EP claimed
EP-1713806-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2013-05-08 EP claimed
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2013-02-21 US claimed
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-11-29 US claimed
CN-102803204-A Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds GILEAD COLORADO INC 2012-11-28 CN claimed
US-8273890-B2 Thiophene-imidazopyridines 4SC AG (DE) 2012-09-25 US claimed
EP-1492536-B1 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA (DE) 2012-05-09 EP claimed
EP-2440519-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2012-04-18 EP claimed
WO-2011100769-A2 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2011-08-18 WO claimed
US-5541163-A HYPOTENSIVE AGENTS BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1996-07-30 US claimed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 EP claimed
US-5457022-A Support having silver halide emulsion layer containing atleast one metallocene compound; fog-free and storage stability FUJI PHOTO FILM CO., LTD. (JP) 1995-10-10 US claimed
WO-1994007845-A1 N-(HYDROXYETHYL)BUTANEDIAMIDE DERIVATIVES AS RENIN INHIBITORS BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1994-04-14 WO claimed
WO-1994007846-A1 RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1994-04-14 WO claimed
EP-0589445-A1 Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1994-03-30 EP claimed
EP-0589446-A1 N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1994-03-30 EP claimed
US-5286858-A Antagonist of platelet activating factor YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-02-15 US claimed
EP-0480455-A1 Optically active thienotriazolodiazepine compounds YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1992-04-15 EP claimed
US-4102886-A REACTING A SECONDARY AMINE AND A BENZO(A)QUINOLIZIDINE, REACTING THE PRODUCT WITH AN UNSATURATED NITRILE, ACID, OR ESTER CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1978-07-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER MAP3K10, MAP3K12, MAP3K20 L3MBTL1 2479/4885TSHR 2634/4885ALOX15 2940/4885
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER MAP3K10, MAP3K12, MAP3K20 L3MBTL1 2479/4885TSHR 2634/4885ALOX15 2940/4885
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 L3MBTL1 2506/4885TSHR 3192/4885ALOX15 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.